Skip to main content
OpenTrials
Completed

NCT Number: NCT00719602

Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART

More than 1.5 million deaths of African children under 5 years of age have been due to Plasmodium falciparum malaria. When HIV and malaria are present as coinfections, they enhance each other's progression. The primary purpose of this study is to compare the malarial infection levels in HIV-infected infants and children receiving protease inhibitor (PI)- or non-nucleotide reverse transcriptase inhibitor (NNRTI)-based highly active antiretroviral therapy (HAART).

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 month–35 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

University of North Carolina Lilongwe (12001), Lilongwe, Malawi

Loading trial locations.

About this study

The World Health Organization (WHO) reports 1 to 2 million malaria deaths annually, with most malaria-related deaths occurring in children. The malaria burden is compounded by the HIV epidemic, which is most prevalent in areas endemic for malaria, notably Sub-Saharan Africa where nine in ten children younger than 15 years of age are infected with HIV. The purpose of this study is to compare parasitemia levels in HIV-infected infants and children receiving PI- or NNRTI-based HAART regimens.

This study will enroll a total of 140 participants, 35 from each of the 4 groups in IMPAACT P1060.

This substudy will last until 24 weeks after the last P1060 enrollment or until P1060 study discontinuation. Participants must meet enrollment criteria for P1060 as well as additional criteria for this study. Study visits will occur as a part of P1060 study visits, all of which include a physical exam, blood collection, and assessments of HIV-related symptoms.

Participants are also encouraged to return to the primary clinic site for intercurrent illness visits for assessment, thick and thin blood smear, and filter paper blood collection, however these visits are not mandatory for study participation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Enrolling in study IMPAACT P1060
  • Parent/legal guardian agrees to seek medical care for intercurrent illness at the study site, whenever possible, and agree to not use at-home remedies for febrile illness in the child

Exclusion criteria

None.

Treatment and study plan

Lamivudine

Drug

Taken orally twice daily

Other names: 3TC

Lopinavir/ritonavir

Drug

Taken orally twice daily

Other names: LPV/r

Nevirapine

Drug

Taken orally twice daily

Other names: NVP

Zidovudine

Drug

Taken orally twice daily

Other names: ZDV

Primary outcomes

  1. Parasitemia in blood samples

    Time frame: Throughout study

Secondary outcomes

  1. Time of initiation of treatment for clinical malaria requiring conventional anti-malarial therapy

    Time frame: Throughout study

  2. Severity of malarial disease

    Time frame: Throughout study

  3. Measured anti-malaria IgG, protein in plasma, and mRNA transcripts in PBMC of chemokines

    Time frame: Throughout study

  4. IL4-589C/T genotypes

    Time frame: Throughout study

Sponsors and collaborators

Lead sponsor

International Maternal Pediatric Adolescent AIDS Clinical Trials Group

Network

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • National Institute of Allergy and Infectious Diseases (NIAID)

Registry information

Official study title

P1060 Substudy Comparing Differences in Malaria Parasitemia by Real Time Quantitative PCR in HIV-Infected Infants and Children on PI-Based HAART Versus NNRTI-Based HAART

Important dates

Study start
2009
Primary completion
2013
Study completion
2013
First posted
Jul 21, 2008
Registry last updated
Sep 19, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.